A Phase 3 interventional study of tocilizumab [RoActemra/Actemra] in Rheumatoid Arthritis, sponsored by Hoffmann-La Roche. Completed at 8 sites in Morocco. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-07-10.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 110 studies testing tocilizumab in Arthritis, Rheumatoid — 5 open to participants now, 5 under way, none of them phase 3. tocilizumab · Arthritis, Rheumatoid.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, this one is the 46th largest by enrollment, is one of 14 that started in 2010, is one of 65 in phase 3, and was the 59th registered.
3,337 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.
Browse Arthritis, Rheumatoid studies →5 of the 110 studies testing tocilizumab in Arthritis, Rheumatoid are open now, in 12 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · Sites in United States, Australia, Brazil and 7 more countries
Ages 18+
Marie Hudson, MD · Sites in Canada
Ages 18+
Reade Rheumatology Research Institute · Sites in Netherlands
Ages 18+
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–80
By country, each count listing its studies:
tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
110 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 6 · Phase 3 65 · Phase 4 32
First in 2001; this study’s year is marked. 14 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 121 is above the median of 96 across 2,224 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 97 across the 110 interventional studies. Of the 98 that completed or were terminated, 66 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
88 of 110 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche: 2 open now, 2 under way, none of them phase 3. Of 214 finished, 139 (65%) have results posted.
Among the 219 studies in Arthritis, Rheumatoid by Hoffmann-La Roche, this one is the 73rd largest by enrollment of the 141 interventional ones that give a count, is one of 26 that started in 2010, is one of 85 in phase 3, and was the 131st registered.
Hoffmann-La Roche’s Arthritis, Rheumatoid studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 110 studies testing tocilizumab in Arthritis, Rheumatoid, from their registry updates:
Among Hoffmann-La Roche’s 219 in Arthritis, Rheumatoid:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This open label, single arm study will assess the safety and efficacy of RoActemra/Actemra (tocilizumab) in patients with moderate to severe active rheumatoid arthritis who have an inadequate response to disease-modifying antirheumatic drugs (DMARDs). Patients will receive RoActemra/Actemra at a dose of 8 mg/kg intravenously every 4 weeks for 24 weeks (6 infusions).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: tocilizumab [RoActemra/Actemra]
Drug page: Tocilizumab
8 mg/kg iv every 4 weeks, total of 6 infusions
Percentage of Participants With Adverse Events
Percentage of participants with adverse events (AEs), serious adverse events (SAEs), severe AEs, AEs leading to withdrawal, AEs leading to death, and treatment-related AEs.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24
Percentage of Participants With All-Cause Discontinuation of Tocilizumab by Study Visit
Percentage of participants discontinuing study treatment for any reason at every visit; causes of discontinuation in the summary included AEs, deaths, lost to follo-wup, AE and investigator decision and 'not determined'.
Time frame: Weeks 4, 8, 12, 16, 20, and 24
Change From Baseline in Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) to Highest Value
The difference between baseline and highest values until Week 24 of ALT and AST. The values are measures as international units per liter (UI/L). The change was calculated as the value (highest) at a later timepoint up to Week 24, minus the value at Baseline.
Time frame: Baseline through Week 24
Change From Baseline Low-Density Lipoprotein (LDL) and Total Cholesterol (TC) to Highest Values
Levels of LDL and TC were measured in milligrams/deciliter (mg/dL). Change in LDL and TC were calculated as the value (highest) through Week 24, minus the value at Baseline.
Time frame: Baseline through Week 24
Percentage of Participants With Lipid Elevations by Study Visit
Lipid panel assessed included TC, triglycerides, high-density lipoprotein (HDL), and LDL. Elevations were categorized as follows: LDL cholesterol: Optimal equals (=) less than (\<)100 mg/dL, Near optimal=100-129 mg/dL, Borderline high 130-159 mg/dL, High 160-189 mg/dL, Very High ≥190 mg/dL; Total cholesterol: Desirable \<200 mg/dL, Borderline high 200-239 mg/dL, High ≥240 mg/dL; HDL cholesterol: Low \<40 mg/dL, High ≥60 mg/dL; Triglycerides: Normal \<150 mg/dL, Borderline high 150-199 mg/dL, High 200-499 mg/dL, and Very high ≥500 mg/dL.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24
Disease Activity Score Based on 28-Joint Count (DAS28)
DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the erythrocyte sedimentation rate (ESR; in millimeters per hour \[mm/hour\]) and global health assessment (participant-rated global assessment of disease activity using 10-mm visual analog assessment \[VAS\]); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. DAS28 less than or equal to (≤3.2) = low disease activity, DAS28 greater than (\>)3.2 to less than or equal to (≤) 5.1=moderate to high disease activity; DAS28 \>5.1=high disease activity.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24
Percentage of Participants by DAS28 Response Category
DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hour) and global health assessment (participant-rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. DAS28 ≤3.2 =low disease activity, DAS28 \>3.2 to ≤5.1=moderate to high disease activity; DAS28 \>5.1=high disease activity.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24
Percentage of Participants With a Clinically Meaningful Improvement in Disease Activity
DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hour) and global health assessment (participant-rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. A reduction in DAS28 of at least 1.2 units was considered a clinically meaningful improvement.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24
Time to Achieve Clinically Meaningful Reduction in DAS28
A clinically meaningful improvement in DAS28 was defined as a reduction of at least 1.2 units. Time to achieving clinically meanigful improvement was calculated as the number of days from the first infusion to the first achievement of reduction of 1.2 units in DAS28.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24
Percentage of Participants Achieving Remission (DAS28 <2.6)
DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hour) and global health assessment (participant-rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. Participants with a DAS28 score \<2.6 were considered to have achieved remission.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24
Percentage of Participants With a Response Assessed Using American College of Rheumatology (ACR) Criteria
The ACR response rates ACR20, ACR50, ACR70 are defined as ≥20%, ≥50%, ≥70% improvement, respectively, in: swollen joint count (SJC) (66 joints) and tender joint count (TJC) (68 joints) and 3 of the following 5 assessments: Patient assessment of pain (VAS); Patient global assessment of disease activity (VAS); Investigator global assessment of disease activity (VAS); and acute phase response (ESR or CRP)
Time frame: Weeks 4, 8, 12, 16, 20, and 24
Swollen and Tender Joint Counts
The following 28 joints were assessed by the physician for swelling: metacarpophalangeal I-V (10), thumb interphalangeal (2), hand proximal interphalangeal II-V (8), wrist (2), elbow (2), shoulders (2), and knees (2). The following 28 joints were assessed by the physician for tenderness : metacarpophalangeal I-V (10), thumb interphalangeal (2), hand proximal interphalangeal II-V (8), wrist (2), elbow (2), shoulders (2), and knees (2). The change in SJC and TJC was determined as the difference in values from baseline at each visit.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24
Health Assessment Questionnaire (HAQ)
HAQ was used to assess the physical ability and functional status of participants as well as quality of life. The disability dimension consists of 20 multiple-choice items concerning difficulty in performing 8 common activities of daily living; dressing and grooming, arising, eating, walking, reaching, personal hygiene, gripping and activities. Participants choose from 4 response categories, ranging from 'without any difficulty' (Score=0) to 'unable to do' (Score=3). The change in HAQ was determined as the difference in values from baseline at each visit.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24
Patient Global Assessment of Disease Activity (VAS)
The participant's overall assessment of their current disease activity was displayed on a 100-mm horizontal VAS. The left-hand extreme (0 mm) of the line was described as "no disease activity" (symptom free and no arthritis symptoms) and the right-hand extreme (100 mm) was described as "maximum disease activity" (maximum arthritis disease activity). The change in Patient Global Assessment of Disease Activity was determined as the difference in values from baseline at each visit.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24
Physician's Global Assessment of Disease Activity (VAS)
The physician's assessment of the participant's current disease activity was displayed on a 100-mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme (100 mm) was described as "maximum disease activity". The Physician's Global Assessment of Disease Activity was completed by the Efficacy Assessor who could or could not be a physician. The change in Physician's Global Assessment of Disease Activity was determined as the difference in values from baseline at each visit.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24
Patient Assessment of of Pain (VAS)
The participant's assessment of their current level of pain was displayed on a 100-mm horizontal VAS. The left-hand extreme (0 mm) of the line was described as "no pain" and the right-hand extreme of the line (100 mm) was described as "unbearable pain". The change in participant's perception of pain was determined as the difference in values from baseline at each visit.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24
C-Reactive Protein (CRP)
CRP is an acute phase inflammatory marker. Levels of CRP increase with inflammation. The change in CRP was determined as the difference in values from baseline and at each visit.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24
Erythrocyte Sedimentation Rate (ESR)
ESR indirectly measures how much inflammation is in the body. A higher ESR is indicative of increased inflammation. The change in ESR was determined as the difference in values from baseline at each visit.
Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24
| Milestone | Tocilizumab 8 mg/kg |
|---|---|
| Started | 121 |
| Completed | 100 |
| Not completed | 21 |
| Withdrew: Lost to follow-up | 7 |
| Withdrew: Adverse event | 6 |
| Withdrew: Physician decision | 1 |
| Withdrew: Adverse event and investigator decision | 1 |
| Withdrew: Death | 1 |
| Withdrew: Not determined | 5 |
Percentage of participants discontinuing study treatment for any reason at every visit; causes of discontinuation in the summary included AEs, deaths, lost to follo-wup, AE and investigator decision and 'not determined'.
| percentage of participants | Tocilizumab 8 mg/kg |
|---|---|
| Week 4 | 3.3 |
| Week 8 | 3.3 |
| Week 12 | 2.5 |
| Week 16 | 2.5 |
| Week 20 | 2.5 |
| Week 24 | 3.3 |
The difference between baseline and highest values until Week 24 of ALT and AST. The values are measures as international units per liter (UI/L). The change was calculated as the value (highest) at a later timepoint up to Week 24, minus the value at Baseline.
| UI/L | Tocilizumab 8 mg/kg |
|---|---|
| ALT | 23.6 ± 34.7 |
| AST | 15.8 ± 22.1 |
Levels of LDL and TC were measured in milligrams/deciliter (mg/dL). Change in LDL and TC were calculated as the value (highest) through Week 24, minus the value at Baseline.
| mg/dL | Tocilizumab 8 mg/kg |
|---|---|
| Total cholesterol | 57.2 ± 78.1 |
| LDL cholesterol | 108.6 ± 106.2 |
Lipid panel assessed included TC, triglycerides, high-density lipoprotein (HDL), and LDL. Elevations were categorized as follows: LDL cholesterol: Optimal equals (=) less than (\<)100 mg/dL, Near optimal=100-129 mg/dL, Borderline high 130-159 mg/dL, High 160-189 mg/dL, Very High ≥190 mg/dL; Total cholesterol: Desirable \<200 mg/dL, Borderline high 200-239 mg/dL, High ≥240 mg/dL; HDL cholesterol: Low \<40 mg/dL, High ≥60 mg/dL; Triglycerides: Normal \<150 mg/dL, Borderline high 150-199 mg/dL, High 200-499 mg/dL, and Very high ≥500 mg/dL.
| percentage of participants | Tocilizumab 8 mg/kg |
|---|---|
| LDL Cholesterol: Optimal, Baseline (n=120) | 53.3 |
| LDL Cholesterol: Optimal, Week 4 (n=116) | 32.8 |
| LDL Cholesterol: Optimal, Week 8 (n=112) | 42.9 |
| LDL Cholesterol: Optimal, Week 12 (n=109) | 33.9 |
| LDL Cholesterol: Optimal, Week 16 (n=106) | 18.9 |
| LDL Cholesterol: Optimal, Week 20 (n=102) | 38.2 |
| LDL Cholesterol: Optimal, Week 24 (n=98) | 28.6 |
| LDL Cholesterol: Near Optimal, Baseline (n=120) | 30.8 |
| LDL Cholesterol: Near Optimal, Week 4 (n=116) | 31.9 |
| LDL Cholesterol: Near Optimal, Week 8 (n=112) | 22.3 |
| LDL Cholesterol: Near Optimal, Week 12 (n=109) | 25.7 |
| LDL Cholesterol: Near Optimal, Week 16 (n=106) | 17.9 |
| LDL Cholesterol: Near Optimal, Week 20 (n=102) | 22.5 |
| LDL Cholesterol: Near Optimal, Week 24 (n=98) | 27.6 |
| LDL Cholesterol: Borderline High, Baseline (n=120) | 12.5 |
| LDL Cholesterol: Borderline High, Week 4 (n=116) | 21.6 |
| LDL Cholesterol: Borderline High Week 8 (n=112) | 23.2 |
| LDL Cholesterol: Borderline High, Week 12 (n=109) | 20.2 |
| LDL Cholesterol: Borderline High, Week 16 (n=106) | 15.1 |
| LDL Cholesterol: Brderline High, Week 20 (n=102) | 25.5 |
| LDL Cholesterol: Borderline High, Week 24 (n=98) | 29.6 |
| LDL Cholesterol: High, Baseline (n=120) | 2.5 |
| LDL Cholesterol: High, Week 4 (n=116) | 7.8 |
| LDL Cholesterol: High, Week 8 (n=112) | 9.8 |
| LDL Cholesterol: High, Week 12 (n=109) | 14.7 |
| LDL Cholesterol: High, Week 16 (n=106) | 9.4 |
| LDL Cholesterol: High, Week 20 (n=102) | 10.8 |
| LDL Cholesterol: High, Week 24 (n=98) | 9.2 |
| LDL Cholesterol: Very High, Baseline (n=120) | 0.8 |
| LDL Cholesterol: Very High, Week 4 (n=116) | 6.0 |
| LDL Cholesterol: Very High, Week 8 (n=112) | 1.8 |
| LDL Cholesterol: Very High, Week 12 (n=109) | 5.5 |
| LDL Cholesterol: Very High, Week 16 (n=106) | 38.7 |
| LDL Cholesterol: Very High, Week 20 (n=102) | 2.9 |
| LDL Cholesterol: Very High, Week 24 (n=98) | 5.1 |
| TC: Desirable, Baseline (n=120) | 77.5 |
| TC: Desirable, Week 4 (n=116) | 58.6 |
| TC: Desirable, Week 8 (n=85) | 28.6 |
| TC: Desirable, Week 12 (n=109) | 56.0 |
| TC: Desirable, Week 16 (n=106) | 56.6 |
| TC: Desirable, Week 20 (n=103) | 52.4 |
| TC: Desirable, Week 24 (n=98) | 51.0 |
| TC: Borderline High, Baseline (n=120) | 18.3 |
| TC: Borderline High, Week 4 (n=116) | 25.0 |
| TC: Borderline High, Week 8 (n=85) | 28.6 |
| TC: Borderline High, Week 12 (n=109) | 23.9 |
| TC: Borderline High, Week 16 (n=106) | 26.4 |
| TC: Borderline High, Week 20 (n=103) | 28.2 |
| TC: Borderline High, Week 24 (n=98) | 26.5 |
| TC: High, Baseline (n=120) | 4.2 |
| TC: High, Week 4 (n=116) | 16.4 |
| TC: High, Week 8 (n=85) | 18.8 |
| TC: High, Week 12 (n=109) | 20.2 |
| TC: High, Week 16 (n=106) | 17.0 |
| TC: High, Week 20 (n=103) | 19.4 |
| TC: High, Week 24 (n=98) | 22.4 |
| HDL Cholesterol: Low, Baseline (n=49) | 28.1 |
| HDL Cholesterol: Low, Week 4 (n=47) | 12.9 |
| HDL Cholesterol: Low, Week 8 (n=54) | 17.7 |
| HDL Cholesterol: Low, Week 12 (n=42) | 11.0 |
| HDL Cholesterol: Low, Week 16 (n=51) | 24.5 |
| HDL Cholesterol: Low, Week 20 (n=52) | 22.3 |
| HDL Cholesterol: Low, Week 24 (n=48) | 19.4 |
| HDL Cholesterol: High, Baseline (n=49) | 12.4 |
| HDL Cholesterol: High, Week 4 (n=47) | 27.6 |
| HDL Cholesterol: High, Week 8 (n=54) | 30.1 |
| HDL Cholesterol: High, Week 12 (n=42) | 27.5 |
| HDL Cholesterol: High, Week 16 (n=51) | 23.6 |
| HDL Cholesterol: High, Week 20 (n=52) | 28.2 |
| HDL Cholesterol: High, Week 24 (n=48) | 29.6 |
| Triglycerides: Normal, Baseline (n=121) | 88.4 |
| Triglycerides: Normal, Week 4 (n=116) | 40.5 |
| Triglycerides: Normal, Week 8 (n=112) | 82.1 |
| Triglycerides: Normal, Week 12 (n=109) | 80.7 |
| Triglycerides: Normal, Week 16 (n=106) | 82.1 |
| Triglycerides: Normal, Week 20 (n=103) | 75.7 |
| Triglycerides: Normal, Week 24 (n=98) | 72.4 |
| Triglycerides: Borderline High, Baseline (n=121) | 8.3 |
| Triglycerides: Borderline High, Week 4 (n=116) | 28.4 |
| Triglycerides: Borderline High, Week 8 (n=112) | 8.0 |
| Triglycerides: Borderline High, Week 12 (n=109) | 8.3 |
| Triglycerides: Borderline High, Week 16 (n=106) | 8.5 |
| Triglycerides: Borderline High, Week 20 (n=103) | 9.7 |
| Triglycerides: Borderline High, Week 24 (n=98) | 16.3 |
| Triglycerides: High, Baseline (n=121) | 3.3 |
| Triglycerides: High, Week 4 (n=116) | 25.9 |
| Triglycerides: High, Week 8 (n=112) | 9.8 |
| Triglycerides: High, Week 12 (n=109) | 11 |
| Triglycerides: High, Week 16 (n=106) | 8.5 |
| Triglycerides: High, Week 20 (n=103) | 14.6 |
| Triglycerides: High, Week 24 (n=98) | 11.2 |
| Triglycerides: Very High, Baseline (n=121) | 0.0 |
| Triglycerides: Very High, Week 4 (n=116) | 5.2 |
| Triglycerides: Very High, Week 8 (n=112) | 0.0 |
| Triglycerides: Very High, Week 12 (n=109) | 0.0 |
| Triglycerides: Very High, Week 16 (n=106) | 0.9 |
| Triglycerides: Very High, Week 20 (n=103) | 0.0 |
| Triglycerides: Very High, Week 24 (n=98) | 0.0 |
DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the erythrocyte sedimentation rate (ESR; in millimeters per hour \[mm/hour\]) and global health assessment (participant-rated global assessment of disease activity using 10-mm visual analog assessment \[VAS\]); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. DAS28 less than or equal to (≤3.2) = low disease activity, DAS28 greater than (\>)3.2 to less than or equal to (≤) 5.1=moderate to high disease activity; DAS28 \>5.1=high disease activity.
| units on a scale | Tocilizumab 8 mg/kg |
|---|---|
| Baseline (n=117) | 6.2 ± 1.5 |
| Week 4 (n=116) | 4.0 ± 1.6 |
| Week 8 (n=112) | 3.3 ± 1.4 |
| Week 12 (n=109) | 2.8 ± 1.4 |
| Week 16 (n=106) | 2.4 ± 1.4 |
| Week 20 (n=103) | 2.1 ± 1.2 |
| Week 24 (n=99) | 2.0 ± 1.3 |
DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hour) and global health assessment (participant-rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. DAS28 ≤3.2 =low disease activity, DAS28 \>3.2 to ≤5.1=moderate to high disease activity; DAS28 \>5.1=high disease activity.
| percentage of participants | Tocilizumab 8 mg/kg |
|---|---|
| DAS28 ≤3.2, Baseline (n=117) | 0.9 |
| DAS28 ≤3.2, Week 4 (n=116) | 31.9 |
| DAS28 ≤3.2, Week 8 (n=112) | 50.9 |
| DAS28 ≤3.2, Week 12 (n=109) | 67.9 |
| DAS28 ≤3.2, Week 16 (n=106) | 81.1 |
| DAS28 ≤3.2, Week 20 (n=103) | 88.3 |
| DAS28 ≤3.2, Week 24 (n=99) | 83.8 |
| DAS28 >3.2 and ≤5.1, Baseline (n=117) | 25.6 |
| DAS28 >3.2 and ≤5.1, Week 4 (n=116) | 43.1 |
| DAS28 >3.2 and ≤5.1, Week 8 (n=112) | 40.2 |
| DAS28 >3.2 and ≤5.1, Week 12 (n=109) | 25.7 |
| DAS28 >3.2 and ≤5.1, Week 16 (n=106) | 13.2 |
| DAS28 >3.2 and ≤5.1, Week 20 (n=103) | 9.7 |
| DAS28 >3.2 and ≤5.1, Week 24 (n=99) | 13.1 |
| DAS28 >5.1, Baseline (n=117) | 73.5 |
| DAS28 >5.1, Week 4 (n=116) | 25.0 |
| DAS28 >5.1, Week 8 (n=112) | 8.9 |
| DAS28 >5.1, Week 12 (n=109) | 6.4 |
| DAS28 >5.1, Week 16 (n=106) | 5.7 |
| DAS28 >5.1, Week 20 (n=103) | 1.9 |
| DAS28 >5.1, Week 24 (n=99) | 3.0 |
DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hour) and global health assessment (participant-rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. A reduction in DAS28 of at least 1.2 units was considered a clinically meaningful improvement.
| percentage of participants | Tocilizumab 8 mg/kg |
|---|---|
| Baseline | 0 |
| Week 4 | 76.7 |
| Week 8 | 91.1 |
| Week 12 | 91.7 |
| Week 16 | 96.2 |
| Week 20 | 98.1 |
| Week 24 | 100 |
A clinically meaningful improvement in DAS28 was defined as a reduction of at least 1.2 units. Time to achieving clinically meanigful improvement was calculated as the number of days from the first infusion to the first achievement of reduction of 1.2 units in DAS28.
| days | Tocilizumab 8 mg/kg |
|---|---|
| Time to Achieve Clinically Meaningful Reduction in DAS28 | 44.7 ± 29.1 |
DAS28 was calculated from the number of swollen joints and tender joints using the 28-joint count, the ESR (mm/hour) and global health assessment (participant-rated global assessment of disease activity using 10-mm VAS); DAS28 score ranged from 0 to 10, where higher scores correspond to greater disease activity. Participants with a DAS28 score \<2.6 were considered to have achieved remission.
| percentage of participants | Tocilizumab 8 mg/kg |
|---|---|
| Baseline (n=117) | 0.0 |
| Week 4 (n=116) | 16.4 |
| Week 8 (n=112) | 30.4 |
| Week 12 (n=109) | 48.6 |
| Week 16 (n=106) | 63.2 |
| Week 20 (n=103) | 73.8 |
| Week 24 (n=99) | 74.7 |
The ACR response rates ACR20, ACR50, ACR70 are defined as ≥20%, ≥50%, ≥70% improvement, respectively, in: swollen joint count (SJC) (66 joints) and tender joint count (TJC) (68 joints) and 3 of the following 5 assessments: Patient assessment of pain (VAS); Patient global assessment of disease activity (VAS); Investigator global assessment of disease activity (VAS); and acute phase response (ESR or CRP)
| percentage of participants | Tocilizumab 8 mg/kg |
|---|---|
| ACR20, Week 4 (n=121) | 62.0 |
| ACR20, Week 8 (n=112) | 73.2 |
| ACR20, Week 12 (n=109) | 78.9 |
| ACR20, Week 16 (n=106) | 85.8 |
| ACR20, Week 20 (n=103) | 90.3 |
| ACR20, Week 24 (n=99) | 87.9 |
| ACR50, Week 4 (n=116) | 27.6 |
| ACR50, Week 8 (n=112) | 50.0 |
| ACR50, Week 12 (n=109) | 63.3 |
| ACR50, Week 16 (n=106) | 77.4 |
| ACR50, Week 20 (n=103) | 85.4 |
| ACR50, Week 24 (n=99) | 80.8 |
| ACR70, Week 4 (n=115) | 6.9 |
| ACR70, Week 8 (n=112) | 29.5 |
| ACR70, Week 12 (n=109) | 32.1 |
| ACR70, Week 16 (n=106) | 48.1 |
| ACR70, Week 20 (n=103) | 56.3 |
| ACR70, Week 24 (n=99) | 61.6 |
The following 28 joints were assessed by the physician for swelling: metacarpophalangeal I-V (10), thumb interphalangeal (2), hand proximal interphalangeal II-V (8), wrist (2), elbow (2), shoulders (2), and knees (2). The following 28 joints were assessed by the physician for tenderness : metacarpophalangeal I-V (10), thumb interphalangeal (2), hand proximal interphalangeal II-V (8), wrist (2), elbow (2), shoulders (2), and knees (2). The change in SJC and TJC was determined as the difference in values from baseline at each visit.
| joints | Tocilizumab 8 mg/kg |
|---|---|
| SJC Baseline | 10.8 ± 7.4 |
| SJC Week 4 | 4.8 ± 6.0 |
| Change in SJC at Week 4 | 6.0 ± 6.5 |
| SJC Week 8 | 3.1 ± 4.6 |
| Change in SJC at Week 8 | 7.5 ± 6.8 |
| SJC Week 12 | 2.8 ± 4.5 |
| Change in SJC at Week 12 | 7.8 ± 6.9 |
| SJC Week 16 | 1.8 ± 3.4 |
| Change in SJC at Week 16 | 8.9 ± 7.4 |
| SJC Week 20 | 0.9 ± 1.9 |
| Change in SJC at Week 20 | 9.8 ± 7.4 |
| SJC Week 24 | 1.0 ± 2.2 |
| Change in SJC at Week 24 | 9.9 ± 7.6 |
| TJC Baseline | 15.4 ± 8.8 |
| TJC Week 4 | 9.3 ± 7.7 |
| Change in TJC at Week 4 | 6.1 ± 7.6 |
| TJC Week 8 | 6.2 ± 5.7 |
| Change in TJC at Week 8 | 9.1 ± 7.2 |
| TJC Week 12 | 4.7 ± 5.8 |
| Change in TJC at Week 12 | 10.4 ± 7.4 |
| TJC Week 16 | 3.3 ± 4.5 |
| Change in TJC at Week 16 | 12.0 ± 7.6 |
| TJC Week 20 | 2.5 ± 3.5 |
| Change in TJC at Week 20 | 12.7 ± 7.8 |
| TJC Week 24 | 2.3 ± 4.1 |
| Change in TJC at Week 24 | 13.0 ± 8.4 |
HAQ was used to assess the physical ability and functional status of participants as well as quality of life. The disability dimension consists of 20 multiple-choice items concerning difficulty in performing 8 common activities of daily living; dressing and grooming, arising, eating, walking, reaching, personal hygiene, gripping and activities. Participants choose from 4 response categories, ranging from 'without any difficulty' (Score=0) to 'unable to do' (Score=3). The change in HAQ was determined as the difference in values from baseline at each visit.
| score on a scale | Tocilizumab 8 mg/kg |
|---|---|
| Baseline | 1.97 ± 0.82 |
| Week 4 | 1.44 ± 0.83 |
| Change at Week 4 | 0.52 ± 0.55 |
| Week 8 | 1.02 ± 0.73 |
| Change at Week 8 | 0.94 ± 0.72 |
| Week 12 | 0.80 ± 0.70 |
| Change at Week 12 | 1.14 ± 0.79 |
| Week 16 | 0.70 ± 0.77 |
| Change at Week 16 | 1.24 ± 0.91 |
| Week 20 | 0.56 ± 0.66 |
| Change at Week 20 | 1.33 ± 0.86 |
| HAQ Week 24 | 0.56 ± 0.69 |
| Change at Week 24 | 1.32 ± 0.87 |
The participant's overall assessment of their current disease activity was displayed on a 100-mm horizontal VAS. The left-hand extreme (0 mm) of the line was described as "no disease activity" (symptom free and no arthritis symptoms) and the right-hand extreme (100 mm) was described as "maximum disease activity" (maximum arthritis disease activity). The change in Patient Global Assessment of Disease Activity was determined as the difference in values from baseline at each visit.
| mm | Tocilizumab 8 mg/kg |
|---|---|
| Baseline | 64.2 ± 18.6 |
| Week 4 | 40.6 ± 20.7 |
| Change at Week 4 | 23.6 ± 21.5 |
| Week 8 | 28.8 ± 19.8 |
| Change at Week 8 | 35.6 ± 22.0 |
| Week 12 | 21.4 ± 18.1 |
| Change at Week 12 | 42.8 ± 23.8 |
| Week 16 | 18.1 ± 19.2 |
| Change at Week 16 | 46.4 ± 25.2 |
| Week 20 | 11.3 ± 12.3 |
| Change at Week 20 | 53.0 ± 22.0 |
| Week 24 | 12.0 ± 15.3 |
| Change at Week 24 | 51.6 ± 25.3 |
The physician's assessment of the participant's current disease activity was displayed on a 100-mm horizontal VAS. The left-hand extreme of the line (0 mm) was described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme (100 mm) was described as "maximum disease activity". The Physician's Global Assessment of Disease Activity was completed by the Efficacy Assessor who could or could not be a physician. The change in Physician's Global Assessment of Disease Activity was determined as the difference in values from baseline at each visit.
| mm | Tocilizumab 8 mg/kg |
|---|---|
| Baseline | 61.8 ± 18.3 |
| Week 4 | 37.7 ± 20.5 |
| Change at Week 4 | 24.3 ± 20.3 |
| Week 8 | 26.7 ± 19.4 |
| Change at Week 8 | 35.4 ± 21.7 |
| Week 12 | 20.0 ± 17.3 |
| Change at Week 12 | 41.6 ± 23.5 |
| Week 16 | 16.0 ± 18.8 |
| Change at Week 16 | 46.0 ± 24.6 |
| Week 20 | 10.0 ± 10.9 |
| Change at Week 20 | 51.8 ± 21.0 |
| Week 24 | 10.7 ± 13.2 |
| Change at Week 24 | 50.6 ± 23.3 |
The participant's assessment of their current level of pain was displayed on a 100-mm horizontal VAS. The left-hand extreme (0 mm) of the line was described as "no pain" and the right-hand extreme of the line (100 mm) was described as "unbearable pain". The change in participant's perception of pain was determined as the difference in values from baseline at each visit.
| mm | Tocilizumab 8 mg/kg |
|---|---|
| Baseline | 63.4 ± 18.7 |
| Week 4 | 41.4 ± 21.1 |
| Change at Week 4 | 21.9 ± 20.7 |
| Week 8 | 29.1 ± 21.0 |
| Change at Week 8 | 34.5 ± 23.1 |
| Week 12 | 21.4 ± 18.1 |
| Change at Week 12 | 41.7 ± 24.1 |
| Week 16 | 16.3 ± 17.7 |
| Change at Week 16 | 46.6 ± 24.5 |
| Week 20 | 10.6 ± 10.9 |
| Change at Week 20 | 52.3 ± 21.8 |
| Week 24 | 11.3 ± 14.3 |
| Change at Week 24 | 51.5 ± 25.4 |
CRP is an acute phase inflammatory marker. Levels of CRP increase with inflammation. The change in CRP was determined as the difference in values from baseline and at each visit.
| mg/dL | Tocilizumab 8 mg/kg |
|---|---|
| Baseline | 22.9 ± 24.1 |
| Week 4 | 6.5 ± 14.8 |
| Change at Week 4 | 16.6 ± 27.3 |
| Week 8 | 4.9 ± 6.4 |
| Change at Week 8 | 17.7 ± 23.1 |
| Week 12 | 5.1 ± 9.4 |
| Change at Week 12 | 16.8 ± 24.3 |
| Week 16 | 5.2 ± 7.5 |
| Change at Week 16 | 17.2 ± 23.3 |
| Week 20 | 6.1 ± 11.6 |
| Change at Week 20 | 16.0 ± 24.1 |
| Week 24 | 6.7 ± 8.7 |
| Change at Week 24 | 16.1 ± 24.3 |
ESR indirectly measures how much inflammation is in the body. A higher ESR is indicative of increased inflammation. The change in ESR was determined as the difference in values from baseline at each visit.
| mm/hr | Tocilizumab 8 mg/kg |
|---|---|
| Baseline | 31.4 ± 23.3 |
| Week 4 | 9.5 ± 11.7 |
| Change at Week 4 | 21.8 ± 20.1 |
| Week 8 | 8.3 ± 11.6 |
| Change at Week 8 | 22.4 ± 20.7 |
| Week 12 | 8.6 ± 12.0 |
| Change at Week 12 | 22.9 ± 21.3 |
| Week 16 | 8.1 ± 13.0 |
| Change at Week 16 | 23.0 ± 18.9 |
| Week 20 | 7.8 ± 11.3 |
| Change at Week 20 | 22.4 ± 19.4 |
| Week 24 | 8.2 ± 9.7 |
| Change at Week 24 | 22.2 ± 2.4 |
Percentage of participants with adverse events (AEs), serious adverse events (SAEs), severe AEs, AEs leading to withdrawal, AEs leading to death, and treatment-related AEs.
| percentage of participants | Tocilizumab 8 mg/kg |
|---|---|
| AEs | 48.8 |
| SAEs | 10.7 |
| With severe AEs | 8.3 |
| AEs leading to withdrawals | 5.8 |
| AEs leading to death | 0.8 |
| Treatment-related AEs | 10.7 |
| Treatment-related SAEs | 4.1 |
| Treatment-related severe AEs | 5.0 |
Collected over Adverse events (AE) were recorded from the date of first infusion to the end of study visit at Week 24.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tocilizumab 8 mg/kg | — | 13/121 (10.7%) | 59/121 (48.8%) |
| Event | Tocilizumab 8 mg/kg |
|---|---|
| Hepatic cytolysisHepatobiliary disorders | 3/121 |
| HypertensionVascular disorders | 2/121 |
| PneumoniaInfections and infestations | 2/121 |
| NeutropeniaBlood and lymphatic system disorders | 1/121 |
| MetrorrhagiaReproductive system and breast disorders | 1/121 |
| Worsening of arthralgiaMusculoskeletal and connective tissue disorders | 1/121 |
| Necrotising fasciitisInfections and infestations | 1/121 |
| BronchitisInfections and infestations | 1/121 |
| Cervical cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/121 |
| Event | Tocilizumab 8 mg/kg |
|---|---|
| Elevation of the AST/ALT levelsInvestigations | 22/121 |
| HypercholesterolemiaInvestigations | 18/121 |
| HypertriglyceridemiaInvestigations | 16/121 |
| Bilirubin level elevationsInvestigations | 15/121 |
| NeutropeniaBlood and lymphatic system disorders | 12/121 |
| ThrombocytopeniaBlood and lymphatic system disorders | 8/121 |
| LeucopeniaBlood and lymphatic system disorders | 5/121 |
| AnaemiaBlood and lymphatic system disorders | 5/121 |
| Increased neutrophil countBlood and lymphatic system disorders | 4/121 |
| Joint painMusculoskeletal and connective tissue disorders | 4/121 |
Intention-to-treat (ITT) population, defined as participants who received at least one dose of tocilizumab (baseline) and for whom data for at least one follow-up variable were available.
| Age, Continuous(years) | Tocilizumab 8 mg/kg |
|---|---|
| Mean | 46.3 ± 12.5 |
| Sex: Female, Male(Participants) | Tocilizumab 8 mg/kg |
|---|---|
| Female | 96 |
| Male | 21 |
The record gives a start of Mar 2010, a primary completion of Aug 2011 and a completion of Aug 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2014, 2 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tocilizumab